International Journal of Hematology

, Volume 92, Issue 5, pp 713–724

Phase II study of ABVd therapy for newly diagnosed clinical stage II–IV Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG 9305)

  • Michinori Ogura
  • Kuniaki Itoh
  • Tomohiro Kinoshita
  • Haruhiko Fukuda
  • Takeaki Takenaka
  • Tomoko Ohtsu
  • Yoshitoyo Kagami
  • Kensei Tobinai
  • Masataka Okamoto
  • Hideki Asaoku
  • Tsuneo Sasaki
  • Chikara Mikuni
  • Masami Hirano
  • Takaaki Chou
  • Kazunori Ohnishi
  • Hitoshi Ohno
  • Kaori Nasu
  • Kenichi Okabe
  • Shuichi Ikeda
  • Shigeo Nakamura
  • Tomomitsu Hotta
  • Masanori Shimoyama
Original Article


Although ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) therapy has been regarded as a standard of care for advanced-stage Hodgkin lymphoma (HL) since 1992, there has been no prospective data of ABVD therapy in Japan. To investigate the efficacy and safety of ABVd therapy with the lower dose of dacarbazine (250 mg/m2) in patients with newly diagnosed stage II–IV HL, Lymphoma Study Group of Japan Clinical Oncology Group conducted a phase II study. The primary endpoints were complete response rate (%CR) and progression-free survival (PFS). A total of 128 patients with age less than 70 years were enrolled and received 6–8 cycles of ABVd followed by radiation to initial bulky mass. The %CR in 118 eligible patients was 81.4% [95% confidence interval (CI) 73.1–87.9%]. Major toxicity was grade 4 neutropenia (45.3%). Grade 3 nausea/vomiting was the most frequent non-hematological toxicity (10.9%). Transient grade 4 constipation, infection (abscess), hypoxemia and hyperbilirubinemia were observed in 4 patients. No treatment-related death was observed. PFS and overall survival at 5 years were 78.4% (95% CI 70.9–85.9%) and 91.3% (95% CI 86.1–96.5%), respectively. In conclusion, ABVd is effective in Japanese patients with stage II–IV HL with acceptable toxicities (UMIN-CTR Number: C000000092).


Hodgkin lymphoma Chemotherapy ABVd therapy Phase II study 


  1. 1.
    Devita VT Jr, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann Intern Med. 1970;73:881–95.PubMedGoogle Scholar
  2. 2.
    Longo DL, Young RC, Wesley M, Hubbard SM, Duffey PL, Jaffe ES, et al. Twenty years of MOPP therapy for Hodgkin’s disease. J Clin Oncol. 1986;4:1295–306.PubMedGoogle Scholar
  3. 3.
    Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C. Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer. 1975;36:252–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Santoro A. Bonadonna G: Prolonged disease-free survival in MOPP-resistant Hodgkin’s disease after treatment with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD). Cancer Chemother Pharmacol. 1979;2:101–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Viviani S, Santoro A, Ragni G, Bonfante V, Bestetti O. Bonadonna G: Gonadal toxicity after combination chemotherapy for Hodgkin’s disease. Comparative results of MOPP vs ABVD. Eur J Cancer Clin Oncol. 1985;21:601–5.PubMedCrossRefGoogle Scholar
  6. 6.
    Bonadonna G, Santoro A, Gianni AM, Viviani S, Siena S, Bregni M, et al. Primary and salvage chemotherapy in advanced Hodgkin’s disease: The Milan Cancer Institute experience. Ann Oncol. 1991;2(Suppl 1):9–16.PubMedGoogle Scholar
  7. 7.
    Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327:1478–84.PubMedCrossRefGoogle Scholar
  8. 8.
    Connors JM. Is cyclic chemotherapy better than standard four-drug chemotherapy for Hodgkin’s disease? Yes. Important Adv Oncol. 1993;189–95.Google Scholar
  9. 9.
    Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial. J Clin Oncol. 2003;21:607–14.PubMedCrossRefGoogle Scholar
  10. 10.
    Lymphoma Study Group of Japanese Pathologists. The World Health Organization classification of malignant lymphomas in Japan: incidence of recently recognized entities. Pathol Int. 2000;50:696–702.CrossRefGoogle Scholar
  11. 11.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2007;58:71–96.CrossRefGoogle Scholar
  12. 12.
    Takenaka T, Mikuni C, Miura A, Sasaki T, Suzuki H, Hotta T, et al. Alternating combination chemotherapy C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adramycin, bleomycin, vinblastine, dacarbazine) in clinical stage II–IV Hodgkin’s disease: a multicenter phase II study (JCOG 8905). Jpn J Clin Oncol. 2000;30:146–52.PubMedCrossRefGoogle Scholar
  13. 13.
    Lukes RJ, Butler JJ. The pathology and nomenclature of Hodgkin’s disease. Cancer Res. 1966;26:1063–83.PubMedGoogle Scholar
  14. 14.
    Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the committee on Hodgkin’s disease staging classification. Cancer Res. 1971;31:1860–1.PubMedGoogle Scholar
  15. 15.
    Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol. 1989;7:1630–6.PubMedGoogle Scholar
  16. 16.
    Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–55.PubMedCrossRefGoogle Scholar
  17. 17.
    Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835–49.PubMedGoogle Scholar
  18. 18.
    WHO Handbook for Reporting Results of Cancer Treatment, WHO Publication, Geneva 1979.Google Scholar
  19. 19.
    Tobinai K, Kohno A, Shimada Y, Watanabe T, Tamura T, Takeyama K, et al. Toxicity grading criteria of the Japan Clinical Oncology Group. Jpn J Clin Oncol. 1993;23:250–7.PubMedGoogle Scholar
  20. 20.
    Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med. 2003;348:2386–95.PubMedCrossRefGoogle Scholar
  21. 21.
    Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International prognostic factors project on advanced Hodgkin’s disease. N Engl J Med. 1998;339:1506–14.PubMedCrossRefGoogle Scholar
  22. 22.
    Viviani S, Bonadonna G, Santoro A, Bonfante V, Zanini M, Devizzi L, et al. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin’s disease: ten-year results. J Clin Oncol. 1996;14:1421–30.PubMedGoogle Scholar
  23. 23.
    Bonadonna G, Valagussa P, Santoro A. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin’s disease. A report of 8-year results. Ann Intern Med. 1986;104:739–46.PubMedGoogle Scholar
  24. 24.
    Somers R, Carde P, Henry-Amar M, Tarayre M, Thomas J, Hagenbeek A, et al. A randomized study in stage IIIB and IV Hodgkin’s disease comparing eight cycles of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial. J Clin Oncol. 1994;12:279–87.PubMedGoogle Scholar
  25. 25.
    Engert A, Diehl V, Franklin J, Lohri A, Dörken B, Ludwig WD, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009;27:4548–54.PubMedCrossRefGoogle Scholar
  26. 26.
    Federico M, Luminari S, Iannitto E, Polimeno G, Marcheselli L, Montanini A, et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin’s lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol. 2009;27:805–11.PubMedCrossRefGoogle Scholar
  27. 27.
    Hoskin PJ, Lowry L, Horwich A, Jack A, Mead B, Hancock BW, et al. Randomized comparison of the Stanford V regimen and ABVD in the treatment of advanced Hodgkin’s Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol. 2009;27:5390–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Aleman BM, Raemaekers JM, Tirelli U, Bortolus R, van‘t Veer MB, Lybeert ML, et al. Involved-field radiotherapy for advanced Hodgkin’s lymphoma. N Engl J Med. 2003;348:2396–406.PubMedCrossRefGoogle Scholar
  29. 29.
    Laskar S, Gupta T, Vimal S, Muckaden MA, Saikia TK, Pai SK, et al. Consolidation radiation after complete remission in Hodgkin’s disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? J Clin Oncol. 2004;22:62–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin’s disease: long-term results. J Clin Oncol. 2004;22:2835–41.PubMedCrossRefGoogle Scholar
  31. 31.
    Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Bezjak A, Wells WA, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin’s lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23:4634–42.PubMedCrossRefGoogle Scholar
  32. 32.
    Cancer Statistics in Japan-2009. Edited by “Cancer Statistics in Japan” Editorial Board, Foundation for Promotion of Cancer Research, 2009, p4.
  33. 33.
    Boleti E, Mead GM. ABVD for Hodgkin’s lymphoma: full-dose chemotherapy without dose reductions or growth factors. Ann Oncol. 2007;18:376–80.PubMedCrossRefGoogle Scholar
  34. 34.
    Brusamolino E, Anselmo AP, Klersy C, Santoro M, Orlandi E, Pagnucco G, et al. The risk of acute leukemia in patients treated for Hodgkin’s disease is significantly higher after combined modality programs compared to chemotherapy alone and correlates with extension of radiotherapy and type and duration of chemotherapy: a case control study. Haematologica. 1998;83:812–23.PubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2010

Authors and Affiliations

  • Michinori Ogura
    • 1
    • 18
  • Kuniaki Itoh
    • 2
  • Tomohiro Kinoshita
    • 3
  • Haruhiko Fukuda
    • 4
  • Takeaki Takenaka
    • 5
    • 19
  • Tomoko Ohtsu
    • 2
    • 20
  • Yoshitoyo Kagami
    • 1
    • 21
  • Kensei Tobinai
    • 5
  • Masataka Okamoto
    • 6
  • Hideki Asaoku
    • 7
  • Tsuneo Sasaki
    • 8
  • Chikara Mikuni
    • 9
    • 22
  • Masami Hirano
    • 6
  • Takaaki Chou
    • 10
  • Kazunori Ohnishi
    • 11
  • Hitoshi Ohno
    • 12
    • 23
  • Kaori Nasu
    • 13
    • 24
  • Kenichi Okabe
    • 14
    • 25
  • Shuichi Ikeda
    • 15
    • 26
  • Shigeo Nakamura
    • 16
    • 27
  • Tomomitsu Hotta
    • 17
    • 28
  • Masanori Shimoyama
    • 5
  1. 1.Department of Hematology and ChemotherapyAichi Cancer Center HospitalNagoyaJapan
  2. 2.Division of Hematology and OncologyNational Cancer Center Hospital EastKashiwaJapan
  3. 3.Department of Hematology and OncologyNagoya University Graduate School of MedicineNagoyaJapan
  4. 4.JCOG Data Center, Center for Cancer Control and Information ServicesNational Cancer CenterTokyoJapan
  5. 5.Hematology DivisionNational Cancer Center HospitalTokyoJapan
  6. 6.Department of MedicineFujita Health University School of MedicineToyoakeJapan
  7. 7.Department of HematologyHiroshima Red Cross HospitalHiroshimaJapan
  8. 8.Department of ChemotherapyTokyo Metropolitan Cancer and Infectious Diseases Center Komagome HospitalTokyoJapan
  9. 9.Department of HematologySapporo National HospitalSapporoJapan
  10. 10.Department of Internal MedicineNiigata Cancer Center HospitalNiigataJapan
  11. 11.The 3rd Department of Internal MedicineHamamatsu University School of MedicineHamamatsuJapan
  12. 12.Department of Hematology and OncologyGraduate School of Medicine, Kyoto UniversityKyotoJapan
  13. 13.Department of HematologyOsaka Red Cross HospitalOsakaJapan
  14. 14.Department of HematologyShikoku National HospitalMatsuyamaJapan
  15. 15.Department of HematologySasebo City General HospitalSaseboJapan
  16. 16.Department of PathologyAichi Cancer Center HospitalNagoyaJapan
  17. 17.Department of Hematology and OncologyTokai University School of MedicineIseharaJapan
  18. 18.Department of Hematology and OncologyNagoya Daini Red Cross HospitalNagoyaJapan
  19. 19.OhubuJapan
  20. 20.Bayer HealthCareBayer Schering PharmaTokyoJapan
  21. 21.Department of HematologyToyota Kosei HospitalToyotaJapan
  22. 22.Sapporo Yuushoukan HospitalSapporoJapan
  23. 23.Department of HematologyTakeda General HospitalKyotoJapan
  24. 24.Nasu Medical ClinicKyotoJapan
  25. 25.Kihoku Town HospitalKitauwagunJapan
  26. 26.Department of Internal MedicineHirado Municipal HospitalHiradoJapan
  27. 27.Department of PathologyNagoya University Graduate School of MedicineNagoyaJapan
  28. 28.National Hospital Organization, Nagoya Medical CenterNagoyaJapan

Personalised recommendations